Joe Milata

446 total citations · 1 hit paper
10 papers, 279 citations indexed

About

Joe Milata is a scholar working on Epidemiology, Genetics and Oncology. According to data from OpenAlex, Joe Milata has authored 10 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 8 papers in Genetics and 3 papers in Oncology. Recurrent topics in Joe Milata's work include Microscopic Colitis (8 papers), Inflammatory Bowel Disease (8 papers) and Colorectal Cancer Treatments and Studies (3 papers). Joe Milata is often cited by papers focused on Microscopic Colitis (8 papers), Inflammatory Bowel Disease (8 papers) and Colorectal Cancer Treatments and Studies (3 papers). Joe Milata collaborates with scholars based in United States, United Kingdom and Japan. Joe Milata's co-authors include Taku Kobayashi, Vipin Arora, Geert D’Haens, Bruce E. Sands, Marla C. Dubinsky, Nathan Morris, Catherine Milch, Xingyuan Li, Peter M. Irving and Kathryn A. Krueger and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Joe Milata

8 papers receiving 270 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2023 170 citations Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joe Milata United States	6	195	145	70	54	51	10	279
Petrease H Patton Canada	4	368 1.9×	280 1.9×	56 0.8×	29 0.5×	97 1.9×	5	489
Marijana Nedeljkovic Protic United Kingdom	3	329 1.7×	266 1.8×	38 0.5×	35 0.6×	147 2.9×	4	383
Antonella Contaldo Italy	9	110 0.6×	126 0.9×	26 0.4×	22 0.4×	89 1.7×	18	291
Ignacio Catalán‐Serra Norway	9	108 0.6×	69 0.5×	94 1.3×	20 0.4×	29 0.6×	21	247
Margalida Calafat Spain	7	138 0.7×	112 0.8×	43 0.6×	17 0.3×	86 1.7×	27	226
Irit Avni‐Biron Israel	9	191 1.0×	149 1.0×	103 1.5×	20 0.4×	120 2.4×	33	309
Berthe‐Marie Imbert France	8	35 0.2×	100 0.7×	86 1.2×	88 1.6×	54 1.1×	16	325
Juliana Silva United Kingdom	6	107 0.5×	103 0.7×	74 1.1×	47 0.9×	31 0.6×	10	222
Valeria Criscuoli Italy	9	262 1.3×	289 2.0×	53 0.8×	28 0.5×	100 2.0×	15	396
C. Tosti Italy	10	129 0.7×	106 0.7×	97 1.4×	10 0.2×	184 3.6×	13	356

Countries citing papers authored by Joe Milata

Since Specialization

Citations

This map shows the geographic impact of Joe Milata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joe Milata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joe Milata more than expected).

Fields of papers citing papers by Joe Milata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joe Milata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joe Milata. The network helps show where Joe Milata may publish in the future.

Co-authorship network of co-authors of Joe Milata

This figure shows the co-authorship network connecting the top 25 collaborators of Joe Milata. A scholar is included among the top collaborators of Joe Milata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joe Milata. Joe Milata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2024). Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases. 31(7). 1876–1890. 14 indexed citations

Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases. 30(12). 2245–2258. 26 indexed citations

Kobayashi, Taku, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.. (2024). Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intestinal Research. 22(2). 172–185. 5 indexed citations

Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2024). S1450 Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study. The American Journal of Gastroenterology. 119(10S). S1043–S1044.

Long, Millie D., Javier P. Gisbert, Kim McGinnis, et al.. (2023). IMPROVEMENT IN BOWEL URGENCY IS ASSOCIATED WITH STOOL FREQUENCY AND RECTAL BLEEDING REMISSION AT 12 AND 52 WEEKS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 29(Supplement_1). S10–S11. 1 indexed citations

Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2023). S848 Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment: Interim Results From the LUCENT-3 Open-Label Extension Study. The American Journal of Gastroenterology. 118(10S). S627–S627. 1 indexed citations

D’Haens, Geert, Marla C. Dubinsky, Taku Kobayashi, et al.. (2023). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 388(26). 2444–2455. 170 indexed citations breakdown →

Dubinsky, Marla C., Peter M. Irving, Xingyuan Li, et al.. (2023). P72 Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results. Poster presentations. A86–A87. 1 indexed citations

Dubinsky, Marla C., Peter M. Irving, Xingyuan Li, et al.. (2022). 867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY. Gastroenterology. 162(7). S–1393. 7 indexed citations

10.

Dunbar, Lala M., et al.. (2011). Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial. Antimicrobial Agents and Chemotherapy. 55(7). 3476–3484. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact